Novo, Johnson and Johnson, Eli Lilly and Novartis are all participants in the neurodegenerative disease drug developer's first funding round.

E-Scape Bio, a spinout of Gladstone Institutes, has achieved a final close of its series A thanks to commitments from Osage University Partners and several corporates.

Monoclonal microbial developer Evelo Biosciences has completed a $50m round featuring GV, Celgene and Mayo Clinic that followed a $35m series A in 2015.

Speech generation device developer Project Vive is the grand prize winner at the Cisco Global Problem Solver Challenge.

The precision medicine company, set up by molecular biology company Qiagen and science park BioBay, will use the money to transition towards a full-fledged products company.

Existing backer Kraft Group returned to take part in a $12.3m round that boosted the oncology diagnostics technology provider's total funding to more than $53m.

Topical skin treatment developer and JLabs graduate Sienna Biopharmaceuticals has filed for a $74.8m initial public offering, after raising $86m in venture funding.

MobileODT has now raised more than $13m altogether, after closing a series B round in which Tristel paid $750,000 for a stake of almost 3.3%.